….to prioritize unhealthy cholesterol as a main public health issue The Global Heart Hub has today launched its Global Cholesterol Action Plan to reduce the […]
RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) (“Relief”), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected […]
• Responds to growing global demand for biosafety testing as essential requirement for drug development and commercialization • Expansion creates more than 500 new jobs […]
– Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients –– Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 […]
…First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment This data suggests the long-term positive […]
Ad hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven […]
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal […]
Bulletin on Drug Safety – Current Issue 3/2022 Published The Bulletin on Drug Safety is a cooperation between the Federal Institute for Drugs and Medical […]
Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion’s Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer […]
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the submission of a New […]
Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced […]
Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant […]
…..to Commercialize Efgartigimod Across Europe and Israel Medison Pharma (“Medison”), a global pharma company focused on providing access to highly innovative therapies to patients in […]
Copyright © 2022 | WordPress Theme by MH Themes
